Probing Calmodulin Protein–Protein Interactions Using High-Content Protein Arrays

Author(s):  
David J. O’Connell ◽  
Mikael Bauer ◽  
Sara Linse ◽  
Dolores J. Cahill
Author(s):  
Christian F. W. Becker ◽  
Ron Wacker ◽  
Werner Bouschen ◽  
Ralf P. Seidel ◽  
Branko Kolaric ◽  
...  

2017 ◽  
pp. 15.21.1-15.21.14 ◽  
Author(s):  
Yanyang Tang ◽  
Ji Qiu ◽  
Matthias Machner ◽  
Joshua LaBaer

Circulation ◽  
2007 ◽  
Vol 116 (suppl_16) ◽  
Author(s):  
Michael L Fitzgerald ◽  
Norimasa Tamehiro ◽  
Suiping Zhou ◽  
Keiichiro Okuhira

Protein microarrays are an emerging high throughput proteomic tool that can be used to study protein-protein interactions. Here we use protein arrays that have 123 PDZ domains spotted in duplicate from 77 PDZ proteins testing over 700 potential interactions and mapping a network of protein interactions that encompasses the ABCA1 transporter and SPLTC1. SPTLC1, through its associated serine palmitoyltransferase activity, catalyzes the initial step in the synthesis of sphingomyelin whose plasma level has been associated with an increased risk of cardiovascular disease. Conversely, ABCA1 effluxes cellular cholesterol to maintain plasma HDL levels which prevents cardiovascular disease. Using hierarchical clustering and networking algorithms analysis of our data set shows PDZ proteins are able to discriminate between closely related PDZ binding motifs contained in the C-termini of ABCA1 and SPTLC1. Mutation of the SPTLC1 PDZ motif disrupted SPTLC1’s ability to bind PDZ proteins and destabilized SPTLC1 protein expression demonstrating the functional importance of the motif. Co-expression of SPTLC1 with ABCA1 in 293 cells inhibited cholesterol efflux activity of the transporter by up to 80% (p < 0.01) as we previously reported and here we show this is through a mechanism that blocks the exit of the transporter from the endoplasmic reticulum. In contrast, treatment of primary human fibroblasts or mouse macrophages with myriocin, a specific serine palmitoyltransferase inhibitor, increased efflux by nearly 60% (p < 0.05). Our results demonstrate the utility using protein arrays to map protein-protein interactions that we hypothesis form a regulatory network that integrates the cholesterol efflux and sphingolipid synthesis pathways. That SPTLC1 activity negatively regulates ABCA1 efflux further suggests inhibition of SPTLC1 activity may represent a new therapeutic target to prevent cardiovascular disease.


2011 ◽  
Vol 49 (08) ◽  
Author(s):  
LC König ◽  
M Meinhard ◽  
C Sandig ◽  
MH Bender ◽  
A Lovas ◽  
...  

1974 ◽  
Vol 31 (03) ◽  
pp. 403-414 ◽  
Author(s):  
Terence Cartwright

SummaryA method is described for the extraction with buffers of near physiological pH of a plasminogen activator from porcine salivary glands. Substantial purification of the activator was achieved although this was to some extent complicated by concomitant extraction of nucleic acid from the glands. Preliminary characterization experiments using specific inhibitors suggested that the activator functioned by a similar mechanism to that proposed for urokinase, but with some important kinetic differences in two-stage assay systems. The lack of reactivity of the pig gland enzyme in these systems might be related to the tendency to protein-protein interactions observed with this material.


2020 ◽  
Author(s):  
Salvador Guardiola ◽  
Monica Varese ◽  
Xavier Roig ◽  
Jesús Garcia ◽  
Ernest Giralt

<p>NOTE: This preprint has been retracted by consensus from all authors. See the retraction notice in place above; the original text can be found under "Version 1", accessible from the version selector above.</p><p><br></p><p>------------------------------------------------------------------------</p><p><br></p><p>Peptides, together with antibodies, are among the most potent biochemical tools to modulate challenging protein-protein interactions. However, current structure-based methods are largely limited to natural peptides and are not suitable for designing target-specific binders with improved pharmaceutical properties, such as macrocyclic peptides. Here we report a general framework that leverages the computational power of Rosetta for large-scale backbone sampling and energy scoring, followed by side-chain composition, to design heterochiral cyclic peptides that bind to a protein surface of interest. To showcase the applicability of our approach, we identified two peptides (PD-<i>i</i>3 and PD-<i>i</i>6) that target PD-1, a key immune checkpoint, and work as protein ligand decoys. A comprehensive biophysical evaluation confirmed their binding mechanism to PD-1 and their inhibitory effect on the PD-1/PD-L1 interaction. Finally, elucidation of their solution structures by NMR served as validation of our <i>de novo </i>design approach. We anticipate that our results will provide a general framework for designing target-specific drug-like peptides.<i></i></p>


2020 ◽  
Author(s):  
Salvador Guardiola ◽  
Monica Varese ◽  
Xavier Roig ◽  
Jesús Garcia ◽  
Ernest Giralt

<p>NOTE: This preprint has been retracted by consensus from all authors. See the retraction notice in place above; the original text can be found under "Version 1", accessible from the version selector above.</p><p><br></p><p>------------------------------------------------------------------------</p><p><br></p><p>Peptides, together with antibodies, are among the most potent biochemical tools to modulate challenging protein-protein interactions. However, current structure-based methods are largely limited to natural peptides and are not suitable for designing target-specific binders with improved pharmaceutical properties, such as macrocyclic peptides. Here we report a general framework that leverages the computational power of Rosetta for large-scale backbone sampling and energy scoring, followed by side-chain composition, to design heterochiral cyclic peptides that bind to a protein surface of interest. To showcase the applicability of our approach, we identified two peptides (PD-<i>i</i>3 and PD-<i>i</i>6) that target PD-1, a key immune checkpoint, and work as protein ligand decoys. A comprehensive biophysical evaluation confirmed their binding mechanism to PD-1 and their inhibitory effect on the PD-1/PD-L1 interaction. Finally, elucidation of their solution structures by NMR served as validation of our <i>de novo </i>design approach. We anticipate that our results will provide a general framework for designing target-specific drug-like peptides.<i></i></p>


Sign in / Sign up

Export Citation Format

Share Document